Daptomycin
The lipopeptide for resistant gram-positive infections, with one use its own label rules out
Daptomycin is a cyclic lipopeptide that punches into gram-positive bacterial membranes. Approved in 2003, it treats complicated skin infections and Staphylococcus aureus bloodstream infections. Its label explicitly rules out pneumonia, because lung surfactant inactivates it.
What is it?
Daptomycin inserts its fatty tail into the membrane of gram-positive bacteria, which lose their membrane potential and die. That mechanism works where resistance to other classes has built up, which is why it is used against methicillin-resistant Staphylococcus aureus.
The Cubicin RF label covers complicated skin and skin-structure infections in adults and children from one year old, and Staphylococcus aureus bloodstream infections in adults, including right-sided endocarditis, and in children aged 1 to 17. It states two limits plainly: not for pneumonia, and not for left-sided endocarditis. Adult dosing is 4 mg/kg once every 24 hours for skin infections and 6 mg/kg for bacteremia, moving to every 48 hours below a creatinine clearance of 30 mL/min. Children get higher weight-based doses the younger they are, up to 10 mg/kg for skin infections and 12 mg/kg for bacteremia under age 7, always as an infusion rather than a two-minute injection.
Its approval for skin infections rests on two randomised trials in 1,092 patients. Daptomycin at 4 mg/kg a day was compared with penicillinase-resistant penicillins or vancomycin; clinical success was 83.4% against 84.2% among 902 evaluable patients, and 63% of daptomycin successes needed only 4 to 7 days of treatment against 33% on the comparators.
In S. aureus bacteremia and endocarditis, the 2006 trial that established it found daptomycin non-inferior to standard therapy. Two later randomised trials tested adding a second drug: adding an anti-staphylococcal beta-lactam to vancomycin or daptomycin did not improve the main outcome in MRSA bacteremia and caused more acute kidney injury, and adding fosfomycin to daptomycin missed its endpoint. A trial comparing daptomycin with vancomycin for MRSA strains less susceptible to vancomycin stopped after enrolling only 14 patients and could not answer its question.
In children with staphylococcal bacteremia, a randomised trial gave 55 children daptomycin and 27 standard care, mainly vancomycin or cefazolin. Clinical success was 88% against 77%, drug-related adverse events occurred in 15% of each group, and daptomycin levels at the age-adjusted doses matched adult exposure at 6 mg/kg. A separate trial established its use for complicated skin infections in children.
The label's pharmacokinetics table gives an elimination half-life of 7.9 to 8.3 hours across 4 to 8 mg/kg in healthy adults, and a population study found clearance tracking kidney function, which is what the dosing interval reflects.
Its warnings centre on muscle: the label asks for creatine kinase monitoring and names rhabdomyolysis, alongside eosinophilic pneumonia, the DRESS reaction, kidney inflammation and peripheral neuropathy. The label also says statins may add to the muscle risk, so they can be paused during treatment, and that daptomycin can falsely prolong the prothrombin time and INR with some laboratory reagents.
Mechanism of Action
Daptomycin inserts its fatty tail into the membrane of gram-positive bacteria, which lose their membrane potential and die.
Membrane depolarisation
Its lipid tail embeds in the bacterial membrane and collapses the membrane potential, a mechanism distinct from other antibiotic classes.
Inactivated in the lung
Lung surfactant inactivates it, which is why the label excludes pneumonia.
Kidney clearance
Clearance tracks kidney function, so the dosing interval doubles to every 48 hours below a creatinine clearance of 30 mL/min (label).
Muscle effects
It can raise creatine kinase and cause myopathy, so the label asks for monitoring and suggests considering a pause in statins.
Published Research
The studies behind daptomycin, read from their PubMed abstracts: the skin-infection and bacteremia trials, combination trials, children, and what drives the dose.
The trial that established it in bacteremia
In 246 patients with S. aureus bloodstream infection with or without endocarditis, success 42 days after treatment was 44.2% with daptomycin at 6 mg/kg and 41.7% with standard therapy, meeting the trial's criteria for non-inferiority. Daptomycin was associated with more microbiological failure.
Two trials in complicated skin infections
In 1,092 patients, clinical success was 83.4% on daptomycin 4 mg/kg a day and 84.2% on penicillinase-resistant penicillins or vancomycin; 63% of daptomycin successes needed only 4 to 7 days of treatment against 33%.
Adding a beta-lactam did not help and caused harm
In 352 adults with MRSA bloodstream infection, adding an antistaphylococcal beta-lactam to vancomycin or daptomycin did not improve the main combined outcome. Bacteremia persisting at day 5 was less common with the combination (11% against 20%), but acute kidney injury was far more common (23% against 6%), and the trial was stopped early on safety grounds.
Adding fosfomycin missed its endpoint
In 155 evaluable patients with MRSA bloodstream infection across 18 Spanish hospitals, treatment success six weeks after therapy was 54.1% with daptomycin plus fosfomycin and 42.0% with daptomycin alone, short of significance (p = 0.135). Microbiological failure was lower with the combination.
Against vancomycin for less-susceptible MRSA, stopped early
The trial stopped after 14 patients for slow recruitment; clearance took a median 4 days in both arms, so it could not show whether daptomycin is better.
Children with complicated skin infections
In 389 children aged 1 to 17 with complicated skin infections, clinical success was 91% on daptomycin and similar on standard care. Diarrhoea (7% against 5%) and raised creatine kinase (6% against 5%) were the most common adverse events.
Children with staphylococcal bacteremia
55 children on daptomycin and 27 on standard care: clinical success 88% against 77%, drug-related adverse events 15% in each group, and drug levels comparable to adults at 6 mg/kg.
What drives the dose
A population analysis pooling 282 subjects from 15 trials found daptomycin clearance varying with kidney function above all, falling to about a third of healthy values in people on dialysis.
Dosing Data
Daptomycin is given intravenously once a day; the label sets the dose by infection type, age and kidney function.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
Side Effects & Contraindications
Reported Side Effects
From the trials above and the Cubicin RF prescribing information (DailyMed set 0b1a8885, version 22, effective March 17, 2025).
Contraindications & Cautions
From the label.
Legal Status
An approved antibiotic, now also generic.
Frequently Asked Questions
?What is daptomycin used for?
Complicated skin and skin-structure infections in adults and children from one year old, and Staphylococcus aureus bloodstream infections in adults, including right-sided endocarditis, and in children aged 1 to 17.
?Why can it not be used for pneumonia?
Its label rules pneumonia out: lung surfactant inactivates the drug, so it does not work there.
?How long does it last in the blood?
The Cubicin RF label gives an elimination half-life of 7.9 to 8.3 hours in healthy adults across 4 to 8 mg/kg, and clearance falls with kidney function.
?What is the main safety concern?
Muscle injury. The label names myopathy and rhabdomyolysis and asks for creatine kinase monitoring, alongside eosinophilic pneumonia, DRESS, kidney inflammation and peripheral neuropathy.
?How well does it work for skin infections?
In two trials in 1,092 patients it matched standard antibiotics (83.4% against 84.2% clinical success), often with a shorter course.
?Can it be taken with a statin?
The label says experience is limited and suggests considering pausing the statin, since both can raise creatine kinase and affect muscle.
?Does it affect blood tests?
Yes. With some laboratory reagents it can falsely prolong the prothrombin time and raise the INR, which the label says can be minimised by timing the blood draw.
References
- [fda-pi] Cubicin RF (daptomycin) prescribing information, sections 1, 2, 5, 6 and 12.3 (DailyMed SPL version 22, effective March 17, 2025; read October 1, 2026).
- [pubmed] Fowler VG Jr, et al. "Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus." N Engl J Med, 2006;355(7):653-65. PMID: 16914701.
- [pubmed] Arbeit RD, et al. "The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections." Clin Infect Dis, 2004;38(12):1673-81. PMID: 15227611.
- [pubmed] Tong SYC, et al. "Effect of Vancomycin or Daptomycin With vs Without an Antistaphylococcal β-Lactam on Mortality, Bacteremia, Relapse, or Treatment Failure in Patients With MRSA Bacteremia: A Randomized Clinical Trial." JAMA, 2020;323(6):527-537. PMID: 32044943.
- [pubmed] Pujol M, et al. "Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial." Clin Infect Dis, 2021;72(9):1517-1525. PMID: 32725216.
- [pubmed] Kalimuddin S, et al. "A randomized phase 2B trial of vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations - results of a prematurely terminated study." Trials, 2018;19(1):305. PMID: 29859132.
- [pubmed] Bradley J, et al. "Daptomycin for Complicated Skin Infections: A Randomized Trial." Pediatrics, 2017;139(3). PMID: 28202770.
- [pubmed] Arrieta AC, et al. "Randomized Multicenter Study Comparing Safety and Efficacy of Daptomycin Versus Standard-of-care in Pediatric Patients With Staphylococcal Bacteremia." Pediatr Infect Dis J, 2018;37(9):893-900. PMID: 29406465.
- [pubmed] Dvorchik B, et al. "Population pharmacokinetics of daptomycin." Antimicrob Agents Chemother, 2004;48(8):2799-807. PMID: 15273084.
Sources & Citations
Studies were read from their PubMed records (October 5, 2026); the label and Drugs@FDA are listed below with their read dates.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.